Concise review: Clinical programs of stem cell therapies for liver and pancreas

Giacomo Lanzoni, Tsunekazu Oikawa, Yunfang Wang, Cai Bin Cui, Guido Carpino, Vincenzo Cardinale, David Gerber, Mara Gabriel, Juan Dominguez-Bendala, Mark E. Furth, Eugenio Gaudio, Domenico Alvaro, Luca A Inverardi, Lola M. Reid

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal-liver-derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100-150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodu-latory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms.

Original languageEnglish
Pages (from-to)2047-2060
Number of pages14
JournalStem Cells
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Cell- and Tissue-Based Therapy
Pancreas
Stem Cells
Liver
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Fetal Stem Cells
Paracrine Communication
Regenerative Medicine
Pancreatic Ducts
Hepatic Artery
Biliary Tract
Standard of Care
Bile Ducts
Islets of Langerhans
Duodenum
Immunosuppression
Liver Diseases
Hepatocytes
Clinical Trials

Keywords

  • Cell transplantation
  • DETERMINED (Adult) stem cells
  • Hematopoietic stem cells
  • Liver
  • Mesenchymal stem cells
  • Pancreas
  • Tissue regeneration
  • Tissue specific stem cells

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Lanzoni, G., Oikawa, T., Wang, Y., Cui, C. B., Carpino, G., Cardinale, V., ... Reid, L. M. (2013). Concise review: Clinical programs of stem cell therapies for liver and pancreas. Stem Cells, 31(10), 2047-2060. https://doi.org/10.1002/stem.1457

Concise review : Clinical programs of stem cell therapies for liver and pancreas. / Lanzoni, Giacomo; Oikawa, Tsunekazu; Wang, Yunfang; Cui, Cai Bin; Carpino, Guido; Cardinale, Vincenzo; Gerber, David; Gabriel, Mara; Dominguez-Bendala, Juan; Furth, Mark E.; Gaudio, Eugenio; Alvaro, Domenico; Inverardi, Luca A; Reid, Lola M.

In: Stem Cells, Vol. 31, No. 10, 01.10.2013, p. 2047-2060.

Research output: Contribution to journalArticle

Lanzoni, G, Oikawa, T, Wang, Y, Cui, CB, Carpino, G, Cardinale, V, Gerber, D, Gabriel, M, Dominguez-Bendala, J, Furth, ME, Gaudio, E, Alvaro, D, Inverardi, LA & Reid, LM 2013, 'Concise review: Clinical programs of stem cell therapies for liver and pancreas', Stem Cells, vol. 31, no. 10, pp. 2047-2060. https://doi.org/10.1002/stem.1457
Lanzoni G, Oikawa T, Wang Y, Cui CB, Carpino G, Cardinale V et al. Concise review: Clinical programs of stem cell therapies for liver and pancreas. Stem Cells. 2013 Oct 1;31(10):2047-2060. https://doi.org/10.1002/stem.1457
Lanzoni, Giacomo ; Oikawa, Tsunekazu ; Wang, Yunfang ; Cui, Cai Bin ; Carpino, Guido ; Cardinale, Vincenzo ; Gerber, David ; Gabriel, Mara ; Dominguez-Bendala, Juan ; Furth, Mark E. ; Gaudio, Eugenio ; Alvaro, Domenico ; Inverardi, Luca A ; Reid, Lola M. / Concise review : Clinical programs of stem cell therapies for liver and pancreas. In: Stem Cells. 2013 ; Vol. 31, No. 10. pp. 2047-2060.
@article{4b72ed92e0344d9da8923b115777ad3f,
title = "Concise review: Clinical programs of stem cell therapies for liver and pancreas",
abstract = "Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal-liver-derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100-150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodu-latory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms.",
keywords = "Cell transplantation, DETERMINED (Adult) stem cells, Hematopoietic stem cells, Liver, Mesenchymal stem cells, Pancreas, Tissue regeneration, Tissue specific stem cells",
author = "Giacomo Lanzoni and Tsunekazu Oikawa and Yunfang Wang and Cui, {Cai Bin} and Guido Carpino and Vincenzo Cardinale and David Gerber and Mara Gabriel and Juan Dominguez-Bendala and Furth, {Mark E.} and Eugenio Gaudio and Domenico Alvaro and Inverardi, {Luca A} and Reid, {Lola M.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1002/stem.1457",
language = "English",
volume = "31",
pages = "2047--2060",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Concise review

T2 - Clinical programs of stem cell therapies for liver and pancreas

AU - Lanzoni, Giacomo

AU - Oikawa, Tsunekazu

AU - Wang, Yunfang

AU - Cui, Cai Bin

AU - Carpino, Guido

AU - Cardinale, Vincenzo

AU - Gerber, David

AU - Gabriel, Mara

AU - Dominguez-Bendala, Juan

AU - Furth, Mark E.

AU - Gaudio, Eugenio

AU - Alvaro, Domenico

AU - Inverardi, Luca A

AU - Reid, Lola M.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal-liver-derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100-150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodu-latory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms.

AB - Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal-liver-derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100-150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodu-latory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms.

KW - Cell transplantation

KW - DETERMINED (Adult) stem cells

KW - Hematopoietic stem cells

KW - Liver

KW - Mesenchymal stem cells

KW - Pancreas

KW - Tissue regeneration

KW - Tissue specific stem cells

UR - http://www.scopus.com/inward/record.url?scp=84887976409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887976409&partnerID=8YFLogxK

U2 - 10.1002/stem.1457

DO - 10.1002/stem.1457

M3 - Article

C2 - 23873634

AN - SCOPUS:84887976409

VL - 31

SP - 2047

EP - 2060

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 10

ER -